Retour
Article pour les cliniciens

Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study.



  • Xu Y
  • Li H
  • Santosa A
  • Wettermark B
  • Fall T
  • Bjork J, et al.
Eur Heart J. 2024 Sep 30:ehae639. doi: 10.1093/eurheartj/ehae639. (Original)
PMID: 39344920
Lire le résumé Lire le texte intégral
Disciplines
  • Médecine interne (voir sous-spécialités ci-dessous)
    Relevance - 6/7
    Intérêt médiatique  - 6/7
  • - Cardiologie
    Relevance - 6/7
    Intérêt médiatique  - 5/7
  • Médecine familiale (MF)/Médecine générale (MG)
    Relevance - 6/7
    Intérêt médiatique  - 5/7
  • Médecine interne générale - Soins primaires
    Relevance - 6/7
    Intérêt médiatique  - 5/7
  • Santé publique
    Relevance - 6/7
    Intérêt médiatique  - 5/7

Résumé (en anglais)

BACKGROUND AND AIMS: While the rationale for coronavirus disease 2019 (COVID-19) vaccination is to reduce complications and overall mortality, some cardiovascular complications from the vaccine itself have been demonstrated. Myocarditis and pericarditis are recognized as rare acute adverse events after mRNA vaccines in young males, while evidence regarding other cardiovascular events remains limited and inconsistent. This study assessed the risks of several cardiovascular and cerebrovascular events in a Swedish nationwide register-based cohort.

METHODS: Post-vaccination risk of myocarditis/pericarditis, dysrhythmias, heart failure, myocardial infarction, and cerebrovascular events (transient ischaemic attack and stroke) in several risk windows after each vaccine dose were assessed among all Swedish adults (n = 8 070 674). Hazard ratios (HRs) with 95% confidence intervals (95% CIs) compared with unvaccinated were estimated from Cox regression models adjusted for potential confounders.

RESULTS: For most studied outcomes, decreased risks of cardiovascular events post-vaccination were observed, especially after dose three (HRs for dose three ranging from .69 to .81), while replicating the increased risk of myocarditis and pericarditis 1-2 weeks after COVID-19 mRNA vaccination. Slightly increased risks, similar across vaccines, were observed for extrasystoles [HR 1.17 (95% CI 1.06-1.28) for dose one and HR 1.22 (95% CI 1.10-1.36) for dose two, stronger in elderly and males] but not for arrhythmias and for transient ischaemic attack [HR 1.13 (95% CI 1.05-1.23), mainly in elderly] but not for stroke.

CONCLUSIONS: Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.


Commentaires cliniques (en anglais)

General Internal Medicine-Primary Care(US)

It's even more important to bring out the cardiovascular events resulting from Covid infections in patients not vaccinated. The incidence of myocarditis pre-COVID is reported at 1 to 10 cases/100,000 individuals; with COVID, the range is 150 to 4000 cases/100,000 individuals. JAMA reported in 2022 the following myocarditis rates in young patients that have a higher rate of this complication: The rates of myocarditis were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively). So when considering risk versus benefit, clearly the benefit it well demonstrated.

Voulez-vous savoir ce que lisent les professionnels? Inscrivez-vous pour accéder gratuitement à tous les contenus professionnels.

S'inscrire